16th National
Conference of the Primary Care Diabetes Society
We are delighted to invite you to virtually attend this year’s National Conference of the Primary Care Diabetes Society (PCDS), our annual, free-to-attend, two-day virtual conference taking place on 5–6 November 2020. The title of this year’s conference is ‘Diabetes in a new world: Crisis, challenge and opportunity’, which reflects not just the evolving situation with COVID-19 but also broader underlying changes in the world of diabetes.
While the format is changing this year, you will, as ever, be able to benefit from clinically focused education on a range of topics that are most relevant to the practicalities of managing diabetes in primary care today. To name just a few of these, we have experts presenting on mental health, prescribing fundamentals, insulin management, the diabetic foot, and the all-important new ways-of-working.
We very much hope that you can join us for this key event in the 2020 diabetes calendar.
Why attend? This fast-paced, interactive conference combines latest clinical guidance, research, case studies and hot topics in diabetes, including lessons learned from COVID-19 and much more
Ask the experts your burning questions through the LIVE Q&A at the end of each session
Log on anytime during the two days from the comfort of your own home to view the sessions
Don’t worry if you miss something, all of the content will be available on-demand
Claim 11 CPD points for the full two-day virtual conference
Agenda for the
16th National Conference 2020
09.15 – 09.25
Session 1
Chair’s introduction
Clare Hambling
09.25 – 09.55
The National picture
- Making use of NDA data
- What will QOF look like in the coming years
- What now for the Diabetes Prevention Programme?
Jonathan Valabhji
15 minute break
10.10 – 10.40
ORAL SEMAGLUTIDE (RYBELSUS®▼) in clinical practice
- This promotional symposium has been organised and funded by Novo Nordisk
- Click here to access Rybelsus (semaglutide tablets) prescribing information & AE reporting
Matt Capehorn & Waqas Tahir
15 minute break
10.55 – 11.25
What has COVID-19 taught us?
- Lessons for diabetes care
- What we can expect in the coming months
Kamlesh Khunti
15 minute break
11.40 – 12.20
Session 2
‘In Practice’ masterclasses
Rotation 1
1. New ways of working post-COVID-19 – performing remote reviews
- The impact of COVID-19 on the provision of routine diabetes reviews in primary care
- Delivering reviews in a way that minimises face-to-face contact – the priorities, processes and practicalities of remote working
- What works well and what improvements can we make?
Jane Diggle
2. Prescribing fundamentals
- Getting the basics right in diabetes care
- Making sense of newer therapies
- Contraindications and other challenges to be on the watch for
Sarah Davies & Sanjay Tanna
3. Insulin
- How to initiate insulin therapy in practice When and how to adjust insulin therapy
- Clinical tips for improving patient care
Su Down
15 minute break
12.35 – 13.05
CREDENCE: A paradigm shift in the management of Diabetic Kidney Disease (DKD)
- This promotional symposium has been organised and funded for by Napp Pharmaceuticals Ltd
James Burton & Amrit Lamba
15 minute break
13.20 – 14.00
Rotation 2
1. New ways of working post-COVID-19 – performing remote reviews
- The impact of COVID-19 on the provision of routine diabetes reviews in primary care
- Delivering reviews in a way that minimises face-to-face contact – the priorities, processes and practicalities of remote working
- What works well and what improvements can we make?
Jane Diggle
2. Prescribing fundamentals
- Getting the basics right in diabetes care
- Making sense of newer therapies
- Contraindications and other challenges to be on the watch for
Sarah Davies & Sanjay Tanna
3. Insulin
- How to initiate insulin therapy in practice When and how to adjust insulin therapy
- Clinical tips for improving patient care
Su Down
15 minute break
14.15 – 14.45
Session 3
Mental health
- What diabetes means for mental health…
- …And what mental health means for diabetes
- Top tips for better practice
Mark Davies
15 minute break
15.00 – 15.30
Managing Cardiovascular risk in Type 2 Diabetes: Evidence into Primary Care Practice
- AstraZeneca promotional symposium
Naresh Kanumilli
15 minute break
15.45 – 16.15
The opportunity that lies in every crisis
- How we can build from the challenges of COVID-19
- Models of improved diabetes care in the coming years
Stephen Lawrence
16.15 – 16.25
Chair’s concluding remarks
Clare Hambling
09.00 – 09.10
Session 4
Chair’s introduction
Clare Hambling
09.10 – 09.40
Heart failure
Yassir Javaid
15 minute break
09.55 – 10.25
Sponsored symposium
09.55 – 10.25
The multiple effects of SGLT2 inhibitors on the Cardio–Renal–Metabolic system in type 2 diabetes
- The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional meeting, including speaker honoraria and presentation support where applicable
- Click here for prescribing Information (UK) JARDIANCE (empagliflozin)
Ameet Bakhai & Partha Kar
15 minute break
10.40 – 11.10
Updates in lifestyle
- Latest evidence on sleep and diabetes
- What is the potential of HIIT?
Jason Gill
15 minute break
11.25 – 12.05
Session 5
‘In Practice’ masterclasses
Rotation 1
1. Diabetic foot disease
- How to examine and assess risk
- Latest advice on management to reduce risk
- When and how to refer in more serious cases
Vanessa Goulding
2. ‘Funny numbers’: Interpreting results
- Making sense of important results for diabetes management
- Expert advice on all the intricacies of getting interpretation right
Clare Hambling & Patrick Wainwright
3. Vulnerable groups in diabetes
- What we can do to improve access to care for vulnerable groups
- Interview style Q&A session
Lisa Devine & Margaret Griffin
4. FreeStyle Libre and Time In Range
- Session organised and supported by Abbott Laboratories Ltd
Emma Wilmot
15 minute break
12.20 – 13.00
Rotation 2
1. Diabetic foot disease
- How to examine and assess risk
- Latest advice on management to reduce risk
- When and how to refer in more serious cases
Vanessa Goulding
2. ‘Funny numbers’: Interpreting results
- Making sense of important results for diabetes management
- Expert advice on all the intricacies of getting interpretation right
Clare Hambling & Patrick Wainwright
3. Vulnerable groups in diabetes
- What we can do to improve access to care for vulnerable groups
- Interview style Q&A session
Lisa Devine & Margaret Griffin
15 minute break
13.15 – 13.45
Session 6
Dietary advice in diabetes
- New data that inform the advice we give
- Practical considerations for helping people with diabetes
Pam Dyson
15 minute break
14.00 – 14.30
Preventing Cardiovascular Events in Type 2 Diabetes
- This is a promotional symposia slot sponsored by Lilly
Yassir Javaid
15 minute break
14.45 – 15.15
Diabetes Distilled
- Emerging evidence from the weeks and months before the conference
Kevin Fernando
15.15 – 15.25
Chair’s concluding remarks
Clare Hambling
09.15 – 09.25
Session 1
Chair’s introduction
Clare Hambling
09.25 – 09.55
The National picture
- Making use of NDA data
- What will QOF look like in the coming years
- What now for the Diabetes Prevention Programme?
Jonathan Valabhji
15 minute break
10.10 – 10.40
ORAL SEMAGLUTIDE (RYBELSUS®▼) in clinical practice
- This promotional symposium has been organised and funded by Novo Nordisk
- Click here to access Rybelsus (semaglutide tablets) prescribing information & AE reporting
Matt Capehorn & Waqas Tahir
15 minute break
10.55 – 11.25
What has COVID-19 taught us?
- Lessons for diabetes care
- What we can expect in the coming months
Kamlesh Khunti
15 minute break
11.40 – 12.20
Session 2
‘In Practice’ masterclasses
Rotation 1
1. New ways of working post-COVID-19 – performing remote reviews
- The impact of COVID-19 on the provision of routine diabetes reviews in primary care
- Delivering reviews in a way that minimises face-to-face contact – the priorities, processes and practicalities of remote working
- What works well and what improvements can we make?
Jane Diggle
2. Prescribing fundamentals
- Getting the basics right in diabetes care
- Making sense of newer therapies
- Contraindications and other challenges to be on the watch for
Sarah Davies & Sanjay Tanna
3. Insulin
- How to initiate insulin therapy in practice When and how to adjust insulin therapy
- Clinical tips for improving patient care
Su Down
15 minute break
12.35 – 13.05
CREDENCE: A paradigm shift in the management of Diabetic Kidney Disease (DKD)
- This promotional symposium has been organised and funded for by Napp Pharmaceuticals Ltd
James Burton & Amrit Lamba
15 minute break
13.20 – 14.00
Rotation 2
1. New ways of working post-COVID-19 – performing remote reviews
- The impact of COVID-19 on the provision of routine diabetes reviews in primary care
- Delivering reviews in a way that minimises face-to-face contact – the priorities, processes and practicalities of remote working
- What works well and what improvements can we make?
Jane Diggle
2. Prescribing fundamentals
- Getting the basics right in diabetes care
- Making sense of newer therapies
- Contraindications and other challenges to be on the watch for
Sarah Davies & Sanjay Tanna
3. Insulin
- How to initiate insulin therapy in practice When and how to adjust insulin therapy
- Clinical tips for improving patient care
Su Down
15 minute break
14.15 – 14.45
Session 3
Mental health
- What diabetes means for mental health…
- …And what mental health means for diabetes
- Top tips for better practice
Mark Davies
15 minute break
15.00 – 15.30
Managing Cardiovascular risk in Type 2 Diabetes: Evidence into Primary Care Practice
- AstraZeneca promotional symposium
Naresh Kanumilli
15 minute break
15.45 – 16.15
The opportunity that lies in every crisis
- How we can build from the challenges of COVID-19
- Models of improved diabetes care in the coming years
Stephen Lawrence
16.15 – 16.25
Chair’s concluding remarks
Clare Hambling
09.00 – 09.10
Session 4
Chair’s introduction
Clare Hambling
09.10 – 09.40
Heart failure
Yassir Javaid
15 minute break
09.55 – 10.25
Sponsored symposium
09.55 – 10.25
The multiple effects of SGLT2 inhibitors on the Cardio–Renal–Metabolic system in type 2 diabetes
- The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional meeting, including speaker honoraria and presentation support where applicable
- Click here for prescribing Information (UK) JARDIANCE (empagliflozin)
Ameet Bakhai & Partha Kar
15 minute break
10.40 – 11.10
Updates in lifestyle
- Latest evidence on sleep and diabetes
- What is the potential of HIIT?
Jason Gill
15 minute break
11.25 – 12.05
Session 5
‘In Practice’ masterclasses
Rotation 1
1. Diabetic foot disease
- How to examine and assess risk
- Latest advice on management to reduce risk
- When and how to refer in more serious cases
Vanessa Goulding
2. ‘Funny numbers’: Interpreting results
- Making sense of important results for diabetes management
- Expert advice on all the intricacies of getting interpretation right
Clare Hambling & Patrick Wainwright
3. Vulnerable groups in diabetes
- What we can do to improve access to care for vulnerable groups
- Interview style Q&A session
Lisa Devine & Margaret Griffin
4. FreeStyle Libre and Time In Range
- Session organised and supported by Abbott Laboratories Ltd
Emma Wilmot
15 minute break
12.20 – 13.00
Rotation 2
1. Diabetic foot disease
- How to examine and assess risk
- Latest advice on management to reduce risk
- When and how to refer in more serious cases
Vanessa Goulding
2. ‘Funny numbers’: Interpreting results
- Making sense of important results for diabetes management
- Expert advice on all the intricacies of getting interpretation right
Clare Hambling & Patrick Wainwright
3. Vulnerable groups in diabetes
- What we can do to improve access to care for vulnerable groups
- Interview style Q&A session
Lisa Devine & Margaret Griffin
15 minute break
13.15 – 13.45
Session 6
Dietary advice in diabetes
- New data that inform the advice we give
- Practical considerations for helping people with diabetes
Pam Dyson
15 minute break
14.00 – 14.30
Preventing Cardiovascular Events in Type 2 Diabetes
- This is a promotional symposia slot sponsored by Lilly
Yassir Javaid
15 minute break
14.45 – 15.15
Diabetes Distilled
- Emerging evidence from the weeks and months before the conference
Kevin Fernando
15.15 – 15.25
Chair’s concluding remarks
Clare Hambling
Conference
Speakers
Mark Davies
Consultant Clinical Psychologist, Belfast Health and Social Care Trust
Sarah Davies
Lisa Devine
GP, Co. Wicklow
Jane Diggle
Specialist Practitioner Practice Nurse, South Kirkby
Su Down
Pam Dyson
Kevin Fernando
GPwSI Diabetes & Medical Education, North Berwick
Jason Gill
Professor of Cardiometabolic Health, Institute of Cardiovascular and Medical Sciences, University of Glasgow
Vanessa Goulding
Highly Specialist Podiatrist, Cardiff Royal Infirmary
Margaret Griffin
Consultant Endocrinologist, Dublin
Clare Hambling
GP, Norfolk, and Chair of the PCDS
Yassir Javaid
Kamlesh Khunti
Professor of Primary Care Diabetes and Vascular Medicine, Leicester
Stephen Lawrence
GPSI, Kent and Associate Clinical Professor, Warwick University Medical School
Sanjay Tanna
Lead Clinical Pharmacist, Blackpool
Jonathan Valabhji
Patrick Wainwright
Emma Wilmot
Conference
Sponsors
GOLD SPONSOR
Napp Pharmaceuticals Limited
Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. We strive to offer new medicines and initiatives that support the NHS in delivering effective, high-quality, sustainable healthcare for the benefit of patients
SILVER SPONSORS
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, there were 201 trials at 376 centres in the UK, involving over 7,000 patients. For more information, please visit www.astrazeneca.co.uk
Boehringer Ingelheim and Lilly Diabetes Alliance
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centres on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need
Eli Lilly and Company Ltd
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.co.uk
Novo Nordisk
At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.
Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.
Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.
For more information visit www.novonordisk.co.uk
Masterclass sponsor
Abbott’s Diabetes Care Division
Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk
BRONZE SPONSORS
AgaMatrix
AgaMatrix manufactures and supplies WaveSense JAZZ™ blood glucose meters, diabetes data management solutions and provides services and support to help you reduce the cost of diabetes care.
With uncompromising accuracy as our cornerstone, we strive to ensure the highest quality diabetes monitoring products and services are supplied at the lowest possible cost.
Find out about our innovative new device, JAZZ™ DoseCoach, the UK’s first evidence-based basal insulin only advisor with built-in blood glucose meter. The device helps patients with type 2 diabetes optimise their once daily insulin glargine dose and is proven to reduce HbA1c.
BD
>1.Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013 Oct;39(5):445-53. doi: 10.1016/j.diabet.2013.05.006. Epub 2013 Jul 22.
Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time.
In the UK, where some of medicines have been helping patients for more than 50 years, we have a portfolio of over 500 products that include branded, generic, over the counter, antiretroviral and biosimilar medicines. Learn more at www.mylan.co.uk.
OTHER SPONSORS
Mundipharma Pharmaceuticals Ltd.
Mundipharma Pharmaceuticals Ltd. has been at the forefront of providing healthcare solutions to the Irish market since 1973. We work at a local level but have all the resources and experience of a global network of independent associated pharmaceutical companies. MPL are actively involved in the development and supply of innovative products, and our focus is directed at improving the quality of life of those suffering from chronic debilitating diseases. Our primary areas of expertise are the areas of diabetes (Invokana® & Vokanamet®), respiratory (flutiform®, flutiform K-haler®), and biosimilars (Pelmeg®, Herzuma® & Truxima®). We look to partnering the medical profession and the patient to manage these conditions over the long term and to seek new and ever better solutions.
Benecol
Making simple switches to your diet can make a big difference. Benecol offer a range of tasty foods with added plant stanols, including yogurt drinks and spreads. The efficacy of plant stanols in Benecol® foods has been proven in over 80 clinical studies, simply having 2g of plant stanols, daily with meals, can lower your cholesterol by 10% on average in just 2-3 weeks*. For more information on how Benecol products with plant stanols work alone or in combination with cholesterol lowering medication come and see us at our stand.
*Plant stanol ester has been shown to lower cholesterol. High cholesterol is a risk factor in the development of coronary heart disease. A daily intake of 1.5–2.4g plant stanols lower cholesterol by 7–10% in 2–3 weeks.
Sanofi
Sanofi is moving beyond conventional thinking in diabetes management. Our advanced treatments and diagnostic tools and support services are just the beginning. Sanofi diabetes are proud to support the PCDS meetings to continue working hard with those who are dedicated to developing diabetes care. Our goal is to develop innovative solutions to help people with diabetes live as people not as patients.
Servier Laboratories
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.6 billion euros in 2019, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests in average 25% of its turnover (excluding generics) every year in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
